Carvolix published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve to restore blood flow and reduce the risk of cardiac insufficiency.
• Preclinical in vivo results published in The Annals of Thoracic Surgery confirm the Epygon mitral valve ability to adapt to the heart while restoring the native-like blood flow.
• Epygon has been designed to replicate the human physiology to allow a better recovery of the left ventricular function minimizing the risk of cardiac insufficiency.
• A first-in-human clinical trial in 15 patients will be initiated in the 2nd semester 2021 and a pivotal study will be initiated in the US and Europe in the 2nd semester 2022.

